Login to Your Account



CV Therapeutics Regains Full Ranexa Rights From Innovex

By Kim Coghill


Monday, July 14, 2003
Promising Phase III data plus a respectable bank account prompted CV Therapeutics Inc. to renegotiate with partner Innovex Inc. for a return of all rights associated with the chronic angina candidate Ranexa. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription